» Articles » PMID: 9935274

Analgesic Nephropathy: is It Caused by Multi-analgesic Abuse or Single Substance Use?

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 1999 Feb 6
PMID 9935274
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Analgesic nephropathy is a slowly progressive renal disease, characterised by renal papillary necrosis. Recently, diagnostic criteria for this disease have been defined based on renal computed tomography scanning performed without contrast. The observation of a decreased renal mass of both kidneys, combined with either bumpy contours or papillary calcifications, has been found to have high diagnostic specificity and sensitivity. However, the question remains as to what kind of analgesics can cause analgesic nephropathy. In the majority of early reports about this condition, phenacetin was singled out as the nephrotoxic culprit. However, during the last decade the nephrotoxic potential of nonphenacetin-containing preparations has become apparent. It is clear that people who abuse analgesics prefer combination analgesics containing 2 analgesics combined with caffeine and/or codeine. In contrast, abuse of products containing only aspirin (acetylsalicylic acid) or paracetamol (acetaminophen) is seldom described and associated renal disease is only occasionally reported. Experimental evidence of the nephrotoxicity of analgesic preparations is not well established. The results of studies involving analgesic administration in animals remain contradictory. Clinical evidence linking high consumption of analgesic preparations with analgesic nephropathy is overwhelming. Most patients who admit to over-consuming analgesics have taken preparation containing more than one compound. In recent years, it has become more apparent that preparations not containing phenacetin also have the potential to cause nephrotoxicity manifesting as identical renal lesions. Further epidemiological evidence of the nephrotoxic potential of analgesic combinations has come from case-control studies published during the last decade and from 2 prospective cohort studies. Effective prevention of analgesic nephropathy consists of the prohibition of over-the-counter sales of preparation containing at least 2 analgesics associated with caffeine and/or codeine.

Citing Articles

Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot.

Ohara K, Akimoto T, Miki T, Otani N, Sugase T, Masuda T Clin Med Insights Case Rep. 2015; 8:97-100.

PMID: 26609249 PMC: 4648563. DOI: 10.4137/CCRep.S32121.


Normal black kidney.

Yarmohamadi A, Akhavan Rezayat A, Memar B, Rahimi H, Cand P Can Urol Assoc J. 2014; 8(3-4):E282-6.

PMID: 24839502 PMC: 4001663. DOI: 10.5489/cuaj.1207.


Development of a community pharmacy-based model to identify and treat OTC drug abuse/misuse: a pilot study.

Fleming G, McElnay J, Hughes C Pharm World Sci. 2004; 26(5):282-8.

PMID: 15598070 DOI: 10.1023/b:phar.0000042891.66983.60.

References
1.
SPUHLER O, ZOLLINGER H . [Chronic interstitial nephritis]. Z Klin Med. 1953; 151(1):1-50. View

2.
Elseviers M, Bosteels V, Cambier P, De Paepe M, Godon J, Lins R . Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant. 1992; 7(6):479-86. View

3.
Larsen K, MOLLER C . A renal lesion caused by abuse of phenacetin. Acta Med Scand. 1959; 164(1):53-71. DOI: 10.1111/j.0954-6820.1959.tb00164.x. View

4.
Jacobs L, Morris J . Renal papillary necrosis and the abuse of phenacetin. Med J Aust. 1962; 49(2):531-8. View

5.
GRIMLUND K . PHENACETIN AND RENAL DAMAGE AT A SWEDISH FACTORY. Acta Med Scand. 1963; 174:SUPPL405:1-26. DOI: 10.1111/j.0954-6820.1963.tb12584.x. View